The Energy Envelope: Pacing for ME/CFS & Long COVID

No, not if exertion itself makes your symptoms worse a day or more afterward (post-exertional malaise, PEM). Pushing through and steadily building activity back up is the graded-exercise-therapy approach, and current UK clinical guidance (NICE NG206) says any programme of fixed, incremental activity increases, including graded exercise therapy, should not be offered for ME/CFS. The CDC takes the same position and warns that pushing through fatigue can trigger post-exertional malaise and worsen the illness. The same PEM mechanism applies whether it shows up under an ME/CFS diagnosis or after long COVID. The safer approach is pacing: staying inside your own energy envelope for physical, cognitive and emotional exertion, with limits set by your symptoms, not a fixed schedule of doing more. If a clinician recommends graded exercise therapy or tells you to just exercise more, that is not in line with current UK and US guidance for ME/CFS.

Track your resting heart rate for about a week to find your baseline, then use it to estimate a rough personal ceiling, many clinicians start with roughly (220 minus your age) times 0.6, or times 0.5 if you are more severely affected, wear a monitor with an alarm set at that number, and rest when it sounds. This threshold is a starting estimate from clinical practice (the Klimas and Sol method), not a number a clinical trial has proven is correct for you. Some clinicians instead use the Workwell Foundation's own method, resting heart rate plus about 15 beats per minute, which is typically more conservative; ask your clinician which starting point they prefer, then refine it against your own crash pattern. Some patients and clinicians report that watching a heart-rate strap closely can become its own source of anxiety, so treat the number as a guide, not a rule to obsess over.

There is no fixed timeline, and that is worth saying plainly rather than guessing at a number. Post-exertional malaise (PEM) is commonly delayed rather than immediate, often starting 24 to 72 hours after the activity that triggered it; the IOM's 2015 clinical report named this delayed pattern as a core diagnostic feature of ME/CFS. How long a crash lasts varies widely: CDC clinical guidance describes PEM lasting anywhere from a day to several weeks, and there is no reliable way to predict your own crash length in advance. If crashes are frequent or severe, that is worth raising with your clinician alongside your pacing plan, never something to push through.

Low-dose naltrexone is a real off-label option some ME/CFS specialists use, and the honest state of the evidence is thin. The largest published ME/CFS dataset is a retrospective look back at the records of 218 Finnish patients treated with LDN, in which about three quarters reported some improvement, most often in alertness and physical or mental performance. That is an open-label chart review with no placebo group, so it cannot separate the drug from normal fluctuation or from expectation. No completed randomised placebo-controlled trial of LDN exists in ME/CFS; one is underway in post-COVID fatigue. Our fibromyalgia page shows what happened when LDN was finally tested properly there: an early small trial looked promising, and every larger randomised trial since has failed to beat placebo. We do not publish a starting dose. Naltrexone is prescription-only, every low dose is compounded, and it blocks opioid painkillers, so the dose belongs to a prescriber who knows your full medication list.

There is no proven treatment for long-COVID brain fog, and anyone selling you one is ahead of the evidence. What specialist consensus guidance actually recommends is unglamorous: find and treat the things that make thinking harder and that can be treated on their own. That means being checked for orthostatic intolerance or POTS, since for many people cognition is measurably worse upright and better lying down; reviewing sleep, mood, medications, iron and thyroid; and pacing mental work the way you pace physical work, because cognitive exertion can trigger post-exertional malaise too. The practical part is accommodation rather than cure: shorter blocks, one task at a time, working reclined, writing things down, reduced hours. Supplements and nootropics marketed for brain fog have no evidence behind them in this population. Computerized brain training has now been tested head to head and did not work: RECOVER-NEURO, the NIH's randomized trial of three non-drug approaches to long-COVID cognitive symptoms (BrainHQ computerized cognitive training, a structured cognitive rehabilitation program, and at-home transcranial direct current stimulation), randomized 328 adults at 22 US sites and found none of the three beat the comparison arm, which was unstructured online puzzles and games. The authors' own conclusion was that the trial failed to show a benefit for any of them (Knopman et al., JAMA Neurology, 2025, PMID 41212544). Grade A on that negative finding, since it is a large multi-site randomized trial. Everyone improved a little, including the comparison group, which is precisely why testimonials for these products are not evidence. Cognitive symptoms that are actively getting worse, rather than persisting, are a reason to be seen by a clinician rather than managed at home.

We cannot tell you whether you have MCAS, and we do not have a mast-cell specialist on our roster, so treat this as an honest map rather than an answer. What is established: symptoms that look like mast cell activation, such as flushing, hives, itching, new food or drug reactions, gut symptoms and sudden heart-rate surges, are reported more often by people with long COVID than by comparison groups. What is contested is whether that pattern is actually mast cell activation syndrome. Two competing sets of diagnostic criteria are in use. The stricter consensus criteria require an objective, event-linked rise in a blood marker (tryptase) rather than symptoms alone, and when people referred for suspected MCAS are assessed against those strict criteria, only a small minority meet them. So a symptom questionnaire is a reason to ask an allergist or immunologist, not a diagnosis. Do not start antihistamines or mast-cell stabilisers as a self-experiment while the question is open.

Some people with ME/CFS work, many work reduced or adjusted hours, and many are not able to work at all. Which of those you end up in is not a measure of how hard you try, and we are not going to promise you an outcome we cannot know. The UK ME/CFS guideline (NICE NG206) treats the impact on employment as substantial and asks employers and clinicians to support people with adjustments rather than expecting a return to previous hours. What tends to matter more than effort: whether the work fits inside your energy envelope, whether it can be done in short blocks, reclined, remotely or at flexible hours, and whether you get recovery time around it. Cognitive work counts as exertion. Testing your capacity by going back full-time to see what happens is the approach most likely to cause a crash. Plan any return with your clinician, ideally with an occupational health assessment, and make every increase reversible.

Sleep hygiene advice alone usually disappoints in ME/CFS because the problem is often abnormal sleep architecture, not a habit to correct. What holds up: protecting sleep regularity and avoiding sedating antihistamines, which can deepen next-day fog (grade B, pacing-adjacent). Melatonin is grade C, one small double-blind trial of melatonin plus zinc improved perceived fatigue, not sleep architecture, and needs replication; NICE guideline NG206 dropped melatonin from its 2021 'consider' list. Skip sleep-debt catch-up framing, forced early wake with bright light plus a walk, and graded exercise sold as a sleep fix, none fit a PEM presentation. Any sleep medication decision, melatonin included, belongs to a clinician familiar with ME/CFS.

Outcomes vary widely; long COVID is not automatically permanent, but it is not guaranteed to resolve either. In the RECOVER-Adult US prospective cohort (n=3,659, mostly Omicron era), among people who met the Long COVID threshold at 3 months, about 19 percent appeared to have recovered by 15 months, about 35 percent had moderate symptoms, and about 46 percent had persistent Long COVID. Separately, 14 percent of the full cohort who did not meet criteria at 3 months had worsened into Long COVID by 15 months. Grade A for 'outcomes vary widely, and worsening after apparent early improvement is documented.' We host no Long COVID specialist on our roster yet, so treat this as cohort data, not a promise; take your own trajectory to a clinician.

This is a partial answer, and we would rather say so than guess. We could not verify a credible, quantified answer about recovery from long COVID at six months, so we publish none rather than approximate one. What is supportable, drawn from NICE NG206 and AAPM&R's PASC guidance already cited on this page: there is no single universal fix. Two things hold up: pacing to avoid post-exertional malaise, and treating the specific, treatable drivers a person actually has, orthostatic intolerance or POTS, sleep, and mast-cell-type symptoms. We are withholding a recovery statistic here because we could not verify one, that is the honest position, not an oversight.

The thing that tells them apart is not your pain, it is what exertion does to you afterwards. The three labels are gated on three different things. ME/CFS is gated on post-exertional malaise: under the 2015 Institute of Medicine criteria (the standard the CDC uses) a person needs a substantial, lasting drop in what they could do before, plus unrefreshing sleep, plus post-exertional malaise, meaning physical, mental or emotional exertion that reliably makes symptoms worse starting hours to about a day later. PEM is mandatory there, not optional. Fibromyalgia is gated on pain: its 2016 American College of Rheumatology criteria turn on generalized pain across the body and how severe the symptom burden is, present at a similar level for at least three months. Post-exertional malaise is not one of its requirements. Long COVID is gated on neither symptom, it is gated on onset: it is an umbrella term for symptoms that begin after a confirmed or probable SARS-CoV-2 infection and persist, at least two months in the World Health Organization's 2021 case definition, twelve weeks or more for what UK NICE guidance NG188 calls post-COVID-19 syndrome. It is a category defined by what started it, not a single illness. So these are not three competing answers to one question. They answer three different questions: what does your pain look like, what does exertion do to you, and what set this off. More than one can be true of the same person at the same time, which is exactly why a fibromyalgia diagnosis does not rule out either of the other two. Grade A on this: it comes straight from the criteria documents, not from an estimate. Only a clinician can diagnose any of these three, so this is what to understand before an appointment, never a way to relabel yourself.

Often enough that it is a normal question. The honest caveat first: the published numbers come from specialist clinics and self-selected surveys, not from the general population, so read them as a signal about how common the overlap is, not as your personal odds. In a Northern California post-COVID clinic, 43 percent of the patients whose symptoms had persisted beyond six months met full ME/CFS criteria, 45 of 105, from 134 patients analysed in total (Bonilla et al., Frontiers in Neurology, 2023, PMID 36908615). A German prospective cohort found about 45 percent (19 of 42) met the Canadian Consensus Criteria for ME/CFS, though that group had already been selected for persistent moderate to severe fatigue and exertion intolerance at six months, so it is an overlap rate inside an already-symptomatic subgroup rather than among all long-COVID patients (Kedor et al., Nature Communications, 2022, volume 13, article 5104). A web survey of 616 people about six months after a COVID diagnosis found roughly 30 percent screened positive for fibromyalgia on modified 2011 ACR criteria, which is self-report rather than a clinical exam (Ursini et al., RMD Open, 2021). Grade C on all three: real peer-reviewed studies, all in referral or self-selected groups, none population-representative. Running the other direction, in the largest and most recent dataset, 45.0 percent of people who met ME/CFS criteria also met fibromyalgia criteria, and 76.1 percent had at least one chronic overlapping pain condition against 17.4 percent of healthy controls (Fall et al., BMC Neurology, 2024, PMID 39425035, 595 patients and 328 controls across seven US specialty clinics, 2012 to 2020). Grade C, still specialty-clinic recruited and cross-sectional. None of this says the three conditions are the same thing. It says the labels describe overlapping, not identical, symptom clusters, and a meaningful share of people in any one bucket would also qualify for another. It also does not tell you which of them you have: meeting criteria on paper is not a diagnosis, and only a clinician can make one.

No, and it is worth saying plainly, because a clean set of results is so often handed to people as proof that nothing is wrong. There is no blood test, scan or biomarker panel that distinguishes these three from each other today. All three are diagnosed clinically, by symptom pattern over time and by ruling out conditions that can look similar. What a reasonable workup is actually checking for is the treatable mimics. CDC guidance on evaluating ME/CFS describes screening bloods including a complete blood count with differential, thyroid function (thyroid stimulating hormone and free thyroxine), inflammatory markers (sedimentation rate and C-reactive protein), antinuclear antibodies and rheumatoid factor, a metabolic panel and urinalysis, and it says that where anemia is found, B12 and folate should be looked at next. A sleep study is reasonable where sleep apnea is suspected, and coeliac antibodies where gut symptoms are prominent. Grade A that no diagnostic test exists, which is definitional across every criteria document for all three conditions; grade B on the specific rule-out list, which comes from clinical guidance rather than a single trial. Normal results on all of that do not disprove your illness. They narrow what else it could be, which is a different job entirely. Ask your clinician what has already been ruled out and what has not, rather than ordering or interpreting these yourself, and remember that only a clinician can make any of these diagnoses.

The post-exertional malaise question, and both halves of it matter. First: after physical, mental or emotional exertion, do your symptoms reliably get worse starting hours to about a day later, rather than immediately? Second: when that happens, does it last more than 24 hours? Yes to both is the strongest single pointer toward ME/CFS, or toward a PEM-driven long COVID presentation, rather than fibromyalgia on its own. Ordinary tiredness right after activity, and pain that flares during activity and settles the same day, are a different pattern. There is a real instrument for this, and the caveat comes before the name: it is a screening aid to bring to an appointment, never a self-diagnosis, and only a clinician can diagnose. The DePaul Symptom Questionnaire post-exertional malaise items (DSQ-PEM) cover how often PEM happens, how severe it is, how long it lasts, and whether you avoid exercise because it makes you worse. Five of those are the items the NIH and CDC Common Data Elements set recommends for ME/CFS research, and the paper that validated them adds five more on duration and recovery (Cotler et al., Diagnostics, 2018, PMID 30208578). Grade B: validated as a screening and research instrument, which is not the same as proving a diagnosis for one person. Use it the way it is meant to be used, which is to fill it out before your appointment so you can describe the pattern precisely instead of reconstructing it under pressure. It does not produce a diagnosis and it is not a score to act on by yourself. Only a clinician can diagnose.

Not in the same way, and the difference is worth being precise about, because it changes what is safe. Pacing as this page describes it exists to prevent exertion-triggered crashes. If post-exertional malaise is part of your picture, whichever of the three labels you carry, pacing comes first and no schedule of steadily rising activity is appropriate. That is not our opinion: UK NICE guidance NG206 withdrew its recommendation for graded exercise therapy in ME/CFS in 2021 because it can cause harm through post-exertional malaise, and this protocol takes the same position. If post-exertional malaise is genuinely absent and widespread pain leads, fibromyalgia-focused management is the better fit, and our Fibromyalgia Pain and Function Protocol covers what the evidence there actually supports, including an honest read of low dose naltrexone and a straight answer on which supplements are not worth your money. The word doing the work in that sentence is genuinely. Absent means asked about and not found, using the two-part question above, not assumed because nobody ever asked. Given that 45.0 percent of people meeting ME/CFS criteria also meet fibromyalgia criteria (Fall et al., BMC Neurology, 2024, PMID 39425035, grade C, a specialty-clinic sample), the overlap is common enough that it is worth checking rather than guessing. If you are not sure, pace first. Pacing costs you activity you might have tolerated. Getting it wrong in the other direction costs you a crash.

The honest frame first: nothing shortens a crash. What the guidance describes is damage limitation, and the most important part of it is that you do not try to carry on. What to do during a crash: stop the activity that triggered it and do not try to push through. Aggressive, complete rest is the only thing that reliably shortens it: lie down in a quiet dim room and cut sensory input (light, noise, screens) and cognitive load (conversation, decisions, planning). Sip water with electrolytes if you can tolerate it. Do not try to walk it off or exercise your way out, which is the one thing that reliably prolongs post-exertional malaise. UK NICE guideline NG206 (recommendation 1.14.5) says that in a flare-up you should temporarily reduce your activity levels and not return to your usual activity levels until the flare-up has resolved; and that in a relapse, meaning a longer and more marked worsening, that means reducing or even stopping some activities, increasing how often and how long you rest, and reassessing your energy limits to stabilise symptoms. In plain terms: stop and rest completely rather than partly, cut things out of the day rather than rescheduling them for later in the week, and when you do start again, start below the level that caused this rather than at it. The Workwell Foundation, whose researchers run the two-day exercise testing that documents post-exertional malaise, states the general recovery principle as resting, hydrating, and minimising activities. Give it time: PEM onset is often delayed 12 to 72 hours after the trigger and a crash can last hours to weeks. Grade C, and it is fairer to call this guideline consensus than graded evidence: there is no randomised trial of crash management, only guideline-body recommendations and patient education from the centres that specialise in this. Some of what circulates as crash advice, such as lying flat or using IV fluids, we deliberately do not list here, because we could not verify it to a source we would stand behind, and IV fluids are a clinician-administered treatment, never a home step. Rest is the right answer for a crash that looks like your crashes usually look. It is the wrong answer when something new is happening: seek urgent medical assessment for chest pain, fainting or near-fainting, severe or worsening breathlessness, a new neurological symptom such as slurred speech, weakness down one side, or a severe headache unlike any you have had before, a fever or other sign of infection, or a crash that does not lift after your usual recovery window. This is information, not medical advice.

Rest is the right answer for a crash that looks the way your crashes usually look. It is the wrong answer when something new is happening. Seek urgent medical assessment for chest pain, fainting or near-fainting, severe or worsening shortness of breath, a new neurological symptom such as slurred speech, weakness down one side, or a severe headache unlike any you have had before, a fever or other sign of infection, or a crash that feels different in kind rather than simply more severe than usual. UK NICE guideline NG206, recommendation 1.14.4, states the principle plainly: evaluate and investigate any new symptoms or a change in symptoms, and do not assume they are caused by the person's ME/CFS. Grade A on that principle, which is safety-netting rather than an estimate. The asymmetry is the whole argument: being checked and sent home costs you an afternoon, and treating a cardiac or neurological event as a bad post-exertional day can cost you far more. Contact your clinician if a crash cannot be managed with your usual approach, if it is lasting markedly longer than your crashes normally do, or if you are simply worried. This is information, not medical advice, and it does not replace an assessment.

The two conditions split on this question, so you are asking for different things. POTS has an objective measurement you can request by name: in adults, a sustained heart-rate rise of 30 beats per minute or more within the first 10 minutes of standing or head-up tilt, without the blood-pressure fall that would point to orthostatic hypotension instead, and between the ages of 12 and 19 the threshold is 40 bpm because heart rate swings more at that age (2015 Heart Rhythm Society expert consensus statement; the within-10-minutes wording is from the StatPearls POTS chapter). Two tests capture it. The head-up tilt table test is done in a lab and is the accepted standard. A 10 minute stand test, also called an active stand test or the NASA Lean Test, can be done in an ordinary clinic room: lying flat for 10 minutes, then standing quietly while heart rate and blood pressure are recorded at intervals out to 10 minutes. Dysautonomia International states that where tilt testing is not available POTS can be diagnosed from those bedside measurements, and says in the same place that a stand test may miss some cases. So the concrete ask is a 10 minute stand test with heart rate and blood pressure taken at each interval and the numbers written into your notes. Grade B: expert consensus and clinical guidance rather than trial evidence. ME/CFS has no equivalent, and that is the part worth being ready for. The NICE 2021 guideline evidence review states that there is no diagnostic test for ME/CFS and that it is recognised on clinical grounds alone, and its criteria are a symptom pattern that has persisted for three months: debilitating fatiguability that rest does not relieve, post-exertional malaise, unrefreshing sleep and cognitive difficulties, together with a substantial reduction in what you could do before. Grade A that no confirmatory test exists, which is definitional. Under that same guideline a diagnosis is followed by referral to an ME/CFS specialist team, so asking for that referral is asking for what the guideline already says should happen. If a named, published standard is not being applied to a real symptom pattern, asking for a second opinion is a reasonable next step and not an overreaction. Bring numbers rather than adjectives: a week or two of heart rate lying down and after standing, and a log of what you did and what happened one to two days afterwards. This is informational only and is not a diagnosis; only a clinician can diagnose POTS or ME/CFS.

Deconditioning is real, and months of reduced activity genuinely do lower fitness, so it is not an unreasonable thing for a clinician to raise. What the evidence does not support is deconditioning as the explanation for ME/CFS, or a build-it-back-up exercise schedule as the answer to it. The strongest objective evidence against that is two-day cardiopulmonary exercise testing. Healthy people, including people who are genuinely deconditioned but otherwise well, reproduce their performance on a second test the next day. People with ME/CFS characteristically cannot: oxygen consumption, work rate and heart rate at submaximal exertion measurably drop on day two despite maximal effort both times. That pattern is not seen in simple deconditioning, which is why ME/CFS is not caused by deconditioning, and it matches the delayed, disproportionate crash patients describe. van Campen, Rowe and Visser (Journal of Translational Medicine, 2021) studied 199 ME/CFS patients and 22 healthy controls who had both a tilt test and a cardiopulmonary exercise test, sorted the patients by how deconditioned they actually were on peak oxygen uptake (85 percent of predicted or above counted as not deconditioned, 65 to 85 percent as mild, under 65 percent as severe), and found the abnormal fall in cerebral blood flow on standing in all of them, with no difference between those groups. Their conclusion is that orthostatic intolerance in ME/CFS is not caused by deconditioning as defined on cardiopulmonary exercise testing. Grade B: one retrospective cohort from a single specialist clinic, not a randomised trial. The safety point outranks the argument. UK guidance is explicit that no ME/CFS treatment programme using fixed or quota-based incremental increases in physical activity or exercise, graded exercise therapy included, should be offered, and that people with ME/CFS should stay within their energy limit rather than push through symptoms (NICE NG206, quoted in a 2022 primary-care review of the guideline in Healthcare). Grade A as guideline. If exertion reliably makes you worse a day or two later, that is post-exertional malaise, and building back up on a schedule is the one approach known to make it worse. Pacing comes first, whatever label is on the chart. If you want something objective for the conversation, the two-day cardiopulmonary exercise test is the test built to show the drop in capacity on the second day that a single test cannot see, and the National Academy of Medicine has recognised it as an objective measure of post-exertional malaise. It is also itself an exertion test that can trigger a crash, which is why the Workwell Foundation does not let patients drive home afterwards, so it is a decision to make with a clinician and never a casual one. This is informational only, not medical advice about your own care, and not a diagnostic tool; only a clinician can diagnose ME/CFS.

There is no cure for ME/CFS today, and we are not going to tell you there is one you missed. What the evidence supports is management, not recovery, and there are real, unfinished pieces of that management worth checking before you conclude nothing is left. First, pacing itself: if you have not tried heart-rate-based pacing specifically (staying under a personal ceiling rather than a general 'take it easy'), that is the single highest-value step on this page and it is free. Second, the treatable comorbidities that commonly ride alongside ME/CFS and get missed: orthostatic intolerance or POTS, thyroid disease, iron deficiency, sleep apnea, and joint hypermobility. None of these fixes ME/CFS itself, but each is independently treatable, and being screened for all of them, not just some, is worth doing before assuming you have exhausted your options. Third, if you have not had an honest conversation with a physician about low-dose naltrexone, that is a real option to discuss, with the evidence limitations named plainly (see our LDN answer above). What we will not do is point you toward IV infusions, stem-cell clinics, long-term antibiotic courses, or frequency devices: none of those has evidence behind it for ME/CFS, and money spent there is money not spent on the things that might actually help. If you have genuinely done all of the above with a specialist and are still stuck, that is a reason to ask for a second specialist opinion, not a sign you have failed at managing this.